Spyre Therapeutics grants 21,424 stock options and 6,604 RSUs to new hires
SYRE•Spyre Therapeutics granted two non-executive employees options covering 21,424 shares and 6,604 restricted stock units under its 2018 Equity Inducement Plan.
1. Award details
The options have a 10-year term and an exercise price of $89.93 per share, the Oct. 1 closing price. Vesting begins with 25% after one year, followed by monthly vesting; the RSUs vest 25% on scheduled quarterly anniversaries.
